Eton Pharmaceuticals (NASDAQ:ETON) PT Raised to $11.00 at HC Wainwright

Eton Pharmaceuticals (NASDAQ:ETON) had its target price upped by HC Wainwright from $9.00 to $11.00 in a research report sent to investors on Friday morning, Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q4 2024 earnings at ($0.01) EPS, Q1 2025 earnings at $0.12 EPS, Q2 2025 earnings at $0.13 EPS, Q3 2025 earnings at $0.16 EPS and Q4 2025 earnings at $0.18 EPS.

Eton Pharmaceuticals Trading Up 4.3 %

Shares of NASDAQ:ETON opened at $7.30 on Friday. The firm has a market capitalization of $187.54 million, a PE ratio of 182.50 and a beta of 1.31. The business’s 50 day moving average is $4.78 and its 200-day moving average is $3.96. Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $7.66.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.05). Eton Pharmaceuticals had a negative return on equity of 43.62% and a negative net margin of 21.31%. The company had revenue of $9.07 million during the quarter, compared to analyst estimates of $10.00 million. On average, sell-side analysts predict that Eton Pharmaceuticals will post -0.15 EPS for the current year.

Insiders Place Their Bets

In related news, major shareholder Opaleye Management Inc. purchased 57,500 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were acquired at an average cost of $4.65 per share, with a total value of $267,375.00. Following the completion of the purchase, the insider now directly owns 2,660,000 shares of the company’s stock, valued at $12,369,000. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 14.89% of the company’s stock.

Hedge Funds Weigh In On Eton Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its position in Eton Pharmaceuticals by 63.8% during the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after purchasing an additional 41,469 shares during the period. Stonepine Capital Management LLC bought a new stake in shares of Eton Pharmaceuticals during the second quarter worth approximately $362,000. Thompson Siegel & Walmsley LLC acquired a new position in Eton Pharmaceuticals in the second quarter valued at approximately $420,000. Acadian Asset Management LLC grew its holdings in Eton Pharmaceuticals by 13.7% during the 1st quarter. Acadian Asset Management LLC now owns 156,386 shares of the company’s stock worth $585,000 after acquiring an additional 18,898 shares during the period. Finally, Aristides Capital LLC bought a new stake in shares of Eton Pharmaceuticals during the 2nd quarter valued at $658,000. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.